LASN-01 is under clinical development by Lassen Therapeutics 1 and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LASN-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LASN-01 is under development for the treatment of thyroid eye disease(TED) or Graves ophthalmopathy, idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung disease (PF-ILD), triple negative breast cancer and skin fibrosis (systemic sclerosis). It acts by targeting interleukin 11 receptor alpha(IL-11R). It is administered through intravenous route.
Lassen Therapeutics 1 overview
Lassen Therapeutics 1 (Lassen Therapeutics) is a biotechnology company developing antibodies for fibrosis, rare diseases and oncology indications. The company is investigating its lead candidate LASN-01, a monoclonal antibody to treat chronic fibrotic, inflammatory diseases and multiple tumor types. Its product candidate targets and blocks interleukin 11 receptor alpha (IL-11R) that acts as a central mediator of fibrosis. The company works in partnership with Cedars-Sinai to develop its products. Lassen Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of LASN-01’s drug-specific PTSR and LoA scores, buy the report here.